#News : A #biosimilar was approved by the FDA today for #psoriaticarthritis and #plaquepsoriasis . We'reproud to continue providing access to treatments for patients living with inflammatory conditions in partnership with Alvotech. ow.ly/fAjA50RhGs2
Today, #FDAapproves Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab): accessdata.fda.gov/drugsatfda_doc…
Wow! Big jump in Sandoz Hyrimoz #biosimilar prescriptions 👇
Credit CVS Health $CVS, which dropped #Humira from its major commercial formularies on 4/1 (See drugch.nl/49EbT5q)
Analysis via Elizabeth Anderson Evercore ISI (Sorry, full report not public.)
EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab esmo.org/esmo/oncology-… 📢 #MedicalOncology #Cancer News #Oncology #Cancer
Insulin shortages are becoming a regular occurrence. Accessible biosimilar insulin could be a beacon of hope for millions, but we need your support to make it a reality. Help us create a future where access to insulin is a right, not a privilege. #insulin4all
Study finds biosimilar adalimumab (Idacio) as effective and safe as Humira for treating inflammatory bowel disease. #IBD #Biosimilars #Adalimumab
Read More: bit.ly/4cWIGFU
Polpharma looks to challenge Takeda’s Entyvio in IBD
#biosimilar #colitis #crohns #vedoluzimab
clinicaltrialsarena.com/news/polpharma…
🌟 Ramsés Gamboa delivered an insightful session at #BiosimilarsLatAm - #Colombia2024 on fostering a winning culture in #biosimilar projects. Highlighting the challenges of uncertainty and risk, he emphasized the importance of simplifying processes to mitigate these challenges.
Erik Perez at #BiosimilarsLatAm - #Colombia2024 highlighted the ongoing efforts of CECMED in updating #biosimilar regulations to align with WHO Guidelines & international standards. Exciting advancements ahead for ensuring quality and accessibility in the Colombian market!
Thanks to CVS Health, a #biosimilar version of AbbVie's #Humira is grabbing huge market share. The big jump was attributed to one biosimilar, #Hyrimoz by Sandoz a former unit of Novartis
Great article ed silverman!
statnews.com/pharmalot/2024… via STAT pharmalot
In 2021, European markets saw a significant rise in biosimilar medicines, reaching €9.7Bn and accounting for 37% of total biologics in treatment days. Explore further insights in our report on Unlocking Biosimilar Potential: bit.ly/4d1poPN. #Biosimilars 💊📈
